Highway to the danger zone? A cautionary account that GLP‐1 receptor agonists may be too effective for unmonitored weight loss
Obesity Reviews · 2024-05 · 25 (5)
DOI: 10.1111/obr.13709 ↗Kurz gefasst
Fachartikel in der Zeitschrift Obesity Reviews, online erschienen am 06.02.2024. Verfasst von Jesse R Richards und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Oklahoma - Tulsa, Tulsa, Oklahoma, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMH NIH HHS, William K. Warren Foundation, National Institute of Mental Health.
Abstract (Originalsprache)
Glucagon‐like peptide 1 (GLP‐1) receptor agonists are revolutionizing obesity and type 2 diabetes treatment, delivering remarkable weight loss outcomes. These medications, leveraging the effects of the insulin‐regulating hormone GLP‐1 via actions on peripheral and central nervous system targets, have raised hopes with their bariatric surgery‐rivaling results. However, questions remain about their long‐term safety and efficacy. Drawing from our expertise in obesity medicine and psychiatry, we reflect upon our experiences with the clinical use of these medications and delve into the nuanced challenges and risks they pose, particularly for those prone to disordered eating or those diagnosed with rare genetic diseases of obesity. We contend that effectively managing weight loss within this “danger zone” necessitates (1) proactive screening and continuous monitoring for disordered eating, (2) vigilant monitoring for appetite‐related maladaptive responses, including food aversion and dehydration, and (3) ongoing assessment for broader health impacts. A multifaceted, interdisciplinary approach that melds medical, psychological, dietary, and behavioral strategies is crucial to delivering tailored and thorough care to each patient.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, University of Oklahoma - Tulsa, Tulsa, Oklahoma, USA.
- Laureate Institute for Brain Research, Tulsa, Oklahoma, USA.
- Oxley College of Health Sciences, University of Tulsa, Tulsa, Oklahoma, USA.
ORCID-Profile: Sahib S Khalsa
Förderung
- NIMH NIH HHS
- William K. Warren Foundation
- National Institute of Mental Health
Zitieren
APA
Richards, J. R., & Khalsa, S. S. (2024). Highway to the danger zone? A cautionary account that GLP‐1 receptor agonists may be too effective for unmonitored weight loss. Obesity Reviews, 25(5). https://doi.org/10.1111/obr.13709
Vancouver
Richards JR, Khalsa SS. Highway to the danger zone? A cautionary account that GLP‐1 receptor agonists may be too effective for unmonitored weight loss. Obesity Reviews. 2024;25(5). doi:10.1111/obr.13709
BibTeX
@article{Richards2024,
author = {Richards, Jesse R and Khalsa, Sahib S},
title = {Highway to the danger zone? A cautionary account that GLP‐1 receptor agonists may be too effective for unmonitored weight loss},
journal = {Obesity Reviews},
year = {2024},
volume = {25},
number = {5},
doi = {10.1111/obr.13709}
}
EUVIMED